INS and Hypoglycemia: In insulin naïve patients with very poor metabolic control, it allows to initiate an injection therapy with minimal risk of hypoglycemia and weight gain, thus overcoming the reluctance to therapy intensification of patients and diabetologists, and reducing clinical inertia [30].